Co-Diagnostics's CoPrimer technology can detect COVID-19 directly from raw saliva

▴ o-Diagnostics's CoPrimer technology can detect COVID-19 directly from raw saliva
Co-Diagnostics, Inc. CoPrimers shown to be effective in COVID-19 saliva PCR tests without sample extraction

Co-Diagnostics, Inc., a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that a recent Company whitepaper demonstrates that the CoPrimer platform technology can be used to identify the presence of SARS-CoV-2 in human saliva samples without first requiring RNA extraction of the sample, and can do so while providing low limits of detection.

The technical advance featured in the whitepaper, found here, was the result of a study into the compatibility of CoPrimer technology with detection of SARS-CoV-2 directly from raw saliva. Various CoPrimer assay configurations were used to consistently detect SARS-CoV-2 in minimally processed saliva in the whitepaper, which concludes that CoPrimers provide a robust platform for the development of such tests.

Dwight Egan, CEO of Co-Diagnostics, commented, "The market for high-throughput, cost-effective COVID-19 tests continues to be strong, and eliminating the costly and time-consuming RNA extraction step allows for even greater speed and economic advantages. We believe the conclusions of this whitepaper speak to the strength, innovation, and flexibility of our CoPrimer platform not just as it relates to creating improved testing technology for COVID-19, but also additional possibilities to implement CoPrimers in various other diagnostic applications. Our next steps include incorporating extraction-free saliva direct tests into the Company product offerings, including those for COVID-19, so they can be available to our customer base world-wide."

Release of the Company whitepaper follows recent news that Clinical Reference Laboratory (CRL) is now selling its CRL Rapid Response saliva-based COVID-19 RT-PCR test directly to consumers. The CRL announcement states that the test uses CoPrimer probes and primers developed by Co-Diagnostics with high degrees of sensitivity and specificity, and a simple saliva collection device that can be administered in virtually any setting, with results in typically 24 hours that are delivered via a secure online computer or mobile device platform.

Mr. Egan continued, "CRL has been an invaluable customer and partner in providing high-quality molecular diagnostic COVID-19 tests to individuals and organizations across the country, helping to facilitate the safe reopening of schools, business, and other organizations. We are pleased that its CRL Rapid Response test will now be even more widely available to consumers online."

Co-Diagnostics' existing CE-marked and FDA EUA Logix Smart COVID-19 test is available to all clinical laboratories certified under Clinical Laboratory Improvement Amendments (CLIA), and is authorized to be used for the diagnosis of SARS-CoV-2, the virus that causes COVID-19, in the US and many other countries.

Tags : #Co-Diagnostics #LatestNewsonCo-Diagnostics11thNov #LatestPharmaNews11thNov #LatestNewsonCOVIDTest11thNov #COVID-19RT-PCRTest

About the Author


Team Medicircle

Related Stories

Loading Please wait...
-Advertisements-


Trending Now

Alembic Pharmaceuticals announces USFDA Final Approval for Metolazone TabletsDecember 03, 2020
QuEST Global provides COVID-19 support kits to more than 1,000 Police Officers in the cityDecember 03, 2020
Gujarat: Series of events mark ‘International Day of Persons with Disabilities’December 03, 2020
Number of COVID-19 positive cases rise in Mizoram, while COVID-19 recovery rate in Tripura improves December 03, 2020
IPC Statement On SARS-CoV-2 Vaccines And PsoriasisDecember 03, 2020
Roche receives USFDA emergency use authorization for new test to measure the level of SARS-CoV-2 antibodiesDecember 03, 2020
Country's COVID recovery rate reaches 94.11 per centDecember 03, 2020
Moderna CEO expects emergency use nod for COVID-19 vaccine after FDA panel meetDecember 03, 2020
Britain becomes first country in world to approve coronavirus vaccineDecember 03, 2020
Roche announces FDA approval of Gavreto for people with advanced or metastatic RET-mutant and RET fusion-positive thyroid cancersDecember 03, 2020
Alembic Pharmaceuticals announces USFDA Final Approval for Metolazone Tablets USPDecember 03, 2020
Replacing red meat with plant foods may reduce the risk of heart diseaseDecember 03, 2020
Birth defects linked to greater risk of cancer in later lifeDecember 03, 2020
Combining telemedicine with AI will increase the productivity of clinicians and quality of care says Srinivas Prasad M R, Member, CII National Committee on Technology and R&DDecember 03, 2020
COVID is an opportunity to reshape the healthcare industry in India says Saurabh Bajpayee, Founder, Oxygenta HealthcareDecember 03, 2020
Second Covid wave expected to hit Karnataka in Jan-FebDecember 03, 2020
COVID19 cases: Maharashtra sees around 50% drop in November compared to October and SeptemberDecember 03, 2020
Moleculin announces FDA approval of 3 Rare pediatric disease designations for WP1066December 03, 2020
Health Decisions and OncoBay Clinical partners for development services in women's oncologyDecember 03, 2020
Impose Community service as penalty on those found violating COVID-19 safety norms: Gujarat High CourtDecember 03, 2020